Cara Therapeutics (NASDAQ: CARA) reported Q4 EPS of ($0.35), $0.02 worse than the analyst estimate of ($0.33).

Financial Guidance

Based on timing expectations and projected costs for current clinical development plans, Cara expects that its existing cash and cash equivalents and available-for-sale marketable securities as of December 31, 2015 will be sufficient for the Company to fund its operating expenses and capital expenditure requirements through the end of the first quarter of 2018, without giving effect to any potential milestone payments under existing collaborations.

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.